Nonsegmental Vitiligo

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2026-03-23
Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) [Phase 3]
STOP-V1 is a Phase 3 study evaluating povorcitinib for nonsegmental vitiligo; the trial is currently active but not recruiting.